Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna RSV vaccine (mRESVIA / mRNA-1345) by Year
RSV vaccine (mRESVIA / mRNA-1345) — Net product sales ($M) ($M)
Moderna RSV vaccine (mRESVIA / mRNA-1345): $8M in FY2025, down 68.0% from a year earlier.
Latest, FY2025
8
Period ended Dec 31, 2025
Change on a year earlier
-68.0%
25 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-Q / 10-K Note 2 (Revenue Disaggregation).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | RSV vaccine (mRESVIA / mRNA-1345) — Net product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8 | -68.0% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 25 | – | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 0 | – | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 0 | – | Form 10-K (filed 2025-02-21) ↗ |
Cite this data
StockData. (2026). Moderna RSV vaccine (mRESVIA / mRNA-1345) ($M), annual FY2022–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/rev-rsv
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.